Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Immunovative Upgrades Manufacturing Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Immunovative Upgrades Manufacturing Facility

Achieves milestone toward commercial cell-based GMP production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Immunovative Therapies, Ltd. (ITL) has completed upgrades to its GMP cell manufacturing facility and GMP operations in Jerusalem to comply with the requirements of advanced clinical trials. The completion and validation of its manufacturing facility will allow the company to launch a Phase II/III trial as planned early in 2013.
 
The facility upgrades include: two class 10,000 cleanroom facilities, interlocked rooms with increasing levels of pressure and air quality, separate rooms for personnel flow and materials flow, clean space for inventory and finished product storage, and product packaging and shipping. ITL has also completed the Installation Qualification (IQ) validation process for the upgraded facility and the Operation Qualification (OQ) and Performance Qualification (PQ). Once PQ is passed, an initial three trial production run will be conducted. If successful, the facility will be brought on-line in April 2013.
 
Dr. Michael Har-Noy, founder and chief executive officer of ITL, said, “We are very pleased with the progress for developing new manufacturing technology solutions and the rapid and cost-effect manner in which these technologies are being transferred to the manufacturing floor. We are also pleased that we have been successful in developing technology enabling the economical distribution of our formulated cell products. The investments in R&D and these new GMP manufacturing facilities are consistent with our strategic plan to become the world’s leading authority for the mass production and distribution of living cell products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics